OBJECTIVES: To assess the effect of donor selection, stool procedures and pretreatment with antibiotics on the efficacy and safety of fecal microbiota transplantation (FMT)-treated ulcerative colitis (UC). METHODS: A systematic review and meta-analysis was conducted including studies on UC treated with FMT as the primary therapeutic agent published up to June 30, 2020. Primary end-point data included clinical remission (CR) or CR combined with endoscopic remission. RESULTS: A total of 37 studies (seven random controlled trials [RCTs], five controlled and 25 uncontrolled cohort studies) and 959 patients with UC were enrolled. In controlled cohort studies and RCTs, FMT had a significantly greater benefit than placebo (pooled odds ratio [P-OR] 3.392, 95% CI 2.196-5.240, P < 0.001), with no heterogeneity (I2 = 0%). Furthermore, administration of FMT via the lower gastrointestinal (GI) tract was more effective in achieving CR than via the upper GI tract (44.3% vs 31.7%). The remission rate was also higher when the total stool dosage was over 275 g compared with less than 275 g (51.9% vs 29.5%). Overall, the incidence of serious adverse events of FMT was 5.9%. There was no significant difference between single and multiple donors, fresh and frozen stool sample used, and whether or not antibiotic pretreatment was administered before FMT. CONCLUSION: FMT administration via the lower GI tract and using higher dosage appear to be effective and safe in inducing remission of active UC.
OBJECTIVES: To assess the effect of donor selection, stool procedures and pretreatment with antibiotics on the efficacy and safety of fecal microbiota transplantation (FMT)-treated ulcerative colitis (UC). METHODS: A systematic review and meta-analysis was conducted including studies on UC treated with FMT as the primary therapeutic agent published up to June 30, 2020. Primary end-point data included clinical remission (CR) or CR combined with endoscopic remission. RESULTS: A total of 37 studies (seven random controlled trials [RCTs], five controlled and 25 uncontrolled cohort studies) and 959 patients with UC were enrolled. In controlled cohort studies and RCTs, FMT had a significantly greater benefit than placebo (pooled odds ratio [P-OR] 3.392, 95% CI 2.196-5.240, P < 0.001), with no heterogeneity (I2 = 0%). Furthermore, administration of FMT via the lower gastrointestinal (GI) tract was more effective in achieving CR than via the upper GI tract (44.3% vs 31.7%). The remission rate was also higher when the total stool dosage was over 275 g compared with less than 275 g (51.9% vs 29.5%). Overall, the incidence of serious adverse events of FMT was 5.9%. There was no significant difference between single and multiple donors, fresh and frozen stool sample used, and whether or not antibiotic pretreatment was administered before FMT. CONCLUSION: FMT administration via the lower GI tract and using higher dosage appear to be effective and safe in inducing remission of active UC.
Authors: Arjun Watane; Kara M Cavuoto; Mario Rojas; Harrison Dermer; Joanne O Day; Santanu Banerjee; Anat Galor Journal: Am J Ophthalmol Date: 2021-06-30 Impact factor: 5.258
Authors: Jessica Emily Green; Jessica A Davis; Michael Berk; Christopher Hair; Amy Loughman; David Castle; Eugene Athan; Andrew A Nierenberg; John F Cryan; Felice Jacka; Wolfgang Marx Journal: Gut Microbes Date: 2020-11-09
Authors: Manuel Ponce-Alonso; Carlota García-Hoz; Ana Halperin; Javier Nuño; Pilar Nicolás; Adolfo Martínez-Pérez; Juan Ocaña; Juan Carlos García-Pérez; Antonio Guerrero; Antonio López-Sanromán; Rafael Cantón; Garbiñe Roy; Rosa Del Campo Journal: Front Immunol Date: 2021-06-04 Impact factor: 7.561
Authors: David J Sanders; Saskia Inniss; Gregory Sebepos-Rogers; Farooq Z Rahman; Andrew M Smith Journal: Biosci Rep Date: 2021-06-25 Impact factor: 3.840